Fatty acids are the primary energy source for the heart. The heart acquires fatty acids associated with albumin or derived from lipoprotein lipase (LpL)-mediated hydrolysis of lipoprotein triglyceride (TG). We generated heart-specific LpL knock-out mice (hLpL0) to determine whether cardiac LpL modulates the actions of peroxisome proliferator-activated receptors and affects whole body lipid metabolism. Male hLpL0 mice had significantly elevated plasma TG levels and decreased clearance of postprandial lipids despite normal postheparin plasma LpL activity. Very large density lipoprotein-TG uptake was decreased by 72% in hLpL0 hearts. However, heart uptake of albumin-bound free fatty acids was not altered. Northern blot analysis revealed a decrease in the expression of peroxisome proliferatoractivated receptor ␣-response genes involved in fatty acid ␤-oxidation. Surprisingly, the expression of glucose transporters 1 and 4 and insulin receptor substrate 2 was increased and that of pyruvate dehydrogenase kinase 4 and insulin receptor substrate 1 was reduced. Basal glucose uptake was increased markedly in hLpL0 hearts. Thus, the loss of LpL in the heart leads to defective plasma metabolism of TG. Moreover, fatty acids derived from lipoprotein TG and not just albumin-associated fatty acids are important for cardiac lipid metabolism and gene regulation.
The heart, unlike most skeletal muscles, is constantly undergoing contraction and relaxation, events that require a large amount of energy. Under normal conditions, the heart derives ϳ70% of its energy from the oxidation of long-chain fatty acids (FA) 1 and the remainder comes from glucose and lactate metabolism (1, 2) . However, a number of conditions including fasting, aerobic exercise, and diabetes increase the contribution of FA to ATP production by the heart (3). FA are supplied to the heart from the hydrolysis of triglyceride (TG)-rich lipoproteins via lipoprotein lipase (LpL) (4) and via uptake of albuminbound FA derived from adipose TG stores. The relative importance of these two pathways for cardiac metabolism and regulation of FA-responsive genes is unknown. LpL controls FA uptake through the hydrolysis of TG in chylomicrons and very large density lipoproteins (VLDL) (5) . Although most lipolysis of plasma TG is thought to occur in skeletal muscle and adipose, several lines of evidence suggest that cardiac muscle is an important site of regulation of plasma TG levels (4, 6) . Cardiac muscle is the tissue with the greatest expression of LpL on a per gram basis (7) . Moreover, mice expressing LpL only in the heart are able to maintain normal lipid levels (4, 6) .
We used the Cre-loxP recombination system to generate mice with a cardiac-specific ablation of the LpL gene to elucidate the role of cardiac LpL in heart and plasma lipoprotein metabolism and gene expression. This allowed us to investigate the role of LpL in the heart without directly altering LpL function and activity in skeletal muscle or adipose tissue. Our data show that the loss of LpL in the heart leads to hypertriglyceridemia and postprandial lipemia. In addition, there was a marked reduction in the expression of key enzymes required for FA metabolism, attesting to the importance of TG-derived FA in cardiac energy metabolism and activation of peroxisome proliferator-activated receptor ␣ (PPAR␣).
MATERIALS AND METHODS

Generation of LpL loxP Mice-A targeting vector was constructed to enable cardiac-specific
Cre-mediated deletion of mouse LpL-exon 1. A 6.5-kb HpaI-BamHI LpL-genomic fragment (including LpL promoter sequences and exon 1) derived from isogenic S129/J DNA (8) was cloned into pBluescript SKϩ. A single loxP site (including a HindIII recognition sequence at the 3Ј end for later screening) was introduced into the LpL-NheI site within intron 1. A XbaI-digested gene cassette containing the neomycin resistance gene and thymidine kinase gene flanked by two loxP sites (9) was inserted into the LpL-SpeI site ϳ0.8 kb upstream of the first exon. The final targeting vector was linearized with NdeI for electroporation into embryonic stem cells. Clones with homologous recombination of the LpL loxP gene were identified, and the neomycin selection cassette was removed by transient expression of cre recombinase. pCre-Pac plasmid containing a puromycin resistance gene was electroporated into homologous recombinant embryonic stem cells. Seven clones positive for the loxP flanked LpL exon 1 and a deletion of * This work was supported by Grants HL45095 and HL073029 from the NHBLI, National Institutes of Health (to I. J. G.). Part of this study was conducted at the Yale Mouse Metabolic Phenotyping Center and supported by the U. S. Public Health Service (Grant U24 DK-59635) and the American Diabetes Association (Grant 7-01-JF-05) (to J. K. K.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.the selection cassette were screened by PCR and injected into the blastocysts of C57BL/6 mice. Chimera mice were obtained, and germ line transmission was confirmed by Southern blotting.
Cardiac-selective LpL-ablated Mice-Mice with cardiomyocyte-selective deletion of LpL were generated by crossing mice heterozygous for the floxed LpL allele with transgenic mice in which cardiac-specific expression of cre recombinase was driven by the ␣-myosin heavy chain promoter (cre) (provided by Dr. Michael Schneider, Baylor University) (10) . Cardiac-specific LpL knock-outs (hLpL0) were then generated by crossing creϩ/lox mice with LpL loxP heterozygous mice (ϩ/lox). The presence of the cre transgene and the modified LpL alleles were verified by PCR and Southern blotting of digested genomic DNA with a 3Ј-BamHI-HindIII probe (Fig. 1A) . For the cre transgene, the following PCR primers were used: 5Ј-ATG ACA GAC AGA TCC CTC CTA-3Ј and 5Ј-CTC ATC ACT TCG TTG CAT CGA C-3Ј. The primers used for identifying the presence of the third loxP site are as follows: 5Ј-CGG CTT AGC TCA GTA CTC AA-3Ј and 5Ј-TCT AGG CAG AGA GCA GCA GA-3Ј.
Heart and Plasma Lipids, FA, and Glucose-We collected blood from 6-h fasted 2-month-old mice and measured plasma lipoproteins by fast performance liquid chromatography as described previously (11) . Heart lipids were extracted as described by Folch et al. (12) . Heart and plasma TG, cholesterol, FA, and glucose were measured enzymatically as described previously (4) . LpL Activity and Mass-Postheparin plasma LpL activity was analyzed as described previously (13) . We injected fasting male mice intravenously with 10 units of heparin and collected blood 10 min later. Plasma samples were assayed in triplicate for LpL activity. LpL activity in homogenized tissues was measured as described by Hocquette et al. (14) . Murine LpL protein was measured by enzyme-linked immunosorbent assay as described previously by van Vlijmen et al. (13) .
Cardiac Muscle Gene Expression-Total RNA (15 g) was isolated from hearts using TRIzol reagent (Invitrogen) and subjected to electrophoresis in 1% agarose gels containing formamide and transferred to nylon filters (Amersham Biosciences). We used the following probes for Northern blotting: murine LpL, acyl-CoA oxidase (ACO), carnitine palmitoyltransferase 1, fatty acid transport protein (FATP), fatty acid translocase (CD36), peroxisome proliferator-activated receptors ␣ and ␥
FIG. 1.
Targeting strategy, LpL expression, and activity. A, diagram of the targeting construct used to generate LpL loxP mice. The black box represents exon 1. H represents HindIII restriction sites used in Southern blotting to identify wild type and modified alleles using the 3Ј probe as shown. Other restriction sites shown include: E, NheI; S, SpeI; Neo, neomycin selection marker; HSV-TK, thymidine kinase. B, Southern blot distinguishing wild type and modified alleles in mice. (ϩ) represents the wild type LpL allele (5.5 kb), and lox represents the loxP-containing allele (4.3 kb). C, 15 g of total RNA obtained from hearts of wild type, cre transgenic, homozygous loxP (lox/lox), and cre homozygous loxP (hLpL0) mice were subjected to Northern blot analysis using a part of cDNA encoding murine LpL as a probe. D, hearts from a second set of mice with the same genotype were homogenized and assayed for LpL activity in triplicate. LpL activity was decreased significantly in hearts from hLpL0 mice compared with wild type, homozygous loxP, and cre transgenic mice (n ϭ 5). E and F, skeletal muscle and adipose tissue from hLpL0 (n ϭ 5) and wild type mice (n ϭ 5) were homogenized and assessed for LpL activity and mass. Values are expressed as percent of control Ϯ S.E. ***, p Ͻ 0.001. Wt, wild type.
(PPAR␣ and PPAR␥), glucose transporters 1 and 4 (GLUT1 and GLUT4), pyruvate dehydrogenase kinase 4 (PDK4), and insulin receptor substrates 1 and 2 (IRS-1 and IRS-2). Results are normalized to glyceraldehyde-3-phosphate dehydrogenase.
Postprandial Lipid Metabolism-We gavaged 2-month old 6-h fasting male hLpL0 and wild type mice with corn oil (10 mg/kg), collected blood from the retro-orbital plexus at 0, 2, 4, 6, 8, and 10 h, and measured plasma TG concentration.
In Vivo Kinetic Studies-In vivo labeling of [ 3 H]VLDL was performed as described previously (15) . [ 14 C]Palmitate (PerkinElmer Life Sciences) was complexed to 6% fatty acid free bovine serum albumin (Sigma) as described previously (16) . We injected fasted hLpL0 and wild type mice intravenously with 1 ϫ 10 6 cpm of [ 3 H]VLDL and 333,000 cpm of [
14 C]palmitate-bovine serum albumin and collected blood at 0.5, 1, 2, and 5 min after injection. 5 min after injection, we perfused the body cavity with 10 ml of phosphate-buffered saline by cardiac puncture and excised tissues.
Immunoblotting-Tissue lysates (40 g) from fed and 6-h fasted mice were subjected to SDS-PAGE and immunoblotting under reducing conditions on 10% gels. Proteins were transferred to nitrocellulose membranes (Bio-Rad), and blots were incubated with primary antibodies to phosphorylated Akt (Ser-473) (Santa Cruz Biotechnology, Santa Cruz, CA).
In Vivo Assessment of Cardiac Glucose Metabolism-Basal glucose uptake was measured in hearts following an intravenous administration of 3 Ci of 2-deoxy-D- [1- 14 C]glucose (PerkinElmer Life Sciences). Blood was collected 2, 5, 15, 30, and 60 min following injection, hearts were perfused with phosphate-buffered saline, tissues were excised, and radioactive counts were measured. A 120-min hyperinsulinemiceuglycemic clamp was conducted in awake hLpL0 mice (n ϭ 5) and wild type littermates (n ϭ 5) by infusing human insulin (Humulin, Novo Nordisk, Princeton, NJ) at a rate of 15 pmol/kg/min. To determine whole body glucose turnover and heart-specific glucose metabolism, [3- 3 H]glucose and 2-deoxy-D-[1-14 C]glucose were administered during clamps as described previously (17) . Tissues were taken at the end of clamps to assess rates of whole body and cardiac glucose metabolism.
Statistics-Data are presented as means Ϯ S.E. Comparisons were made using Student's t test.
RESULTS
Generation and Characterization of Mice with
Cardiac-specific LpL Ablation (hLpL0)-Chimeric mice containing the LpL-floxed allele were crossed with C57BL/6 mice. We then crossed F1 mice, which contained one wild type and one loxPcontaining LpL allele (ϩ/lox) (Fig. 1A) with myosin heavy chain cre-transgenic mice. The offspring were crossed with mice heterozygous for the modified LpL gene, generating mice with a cardiac-specific LpL ablation (hLpL0). This breeding scheme produced six genotypes: cre-transgenic, cre ϩ/lox, cre lox/lox, ϩ/ϩ (wild type), ϩ/lox, and lox/lox. HLpL0 (cre lox/lox) mice were born with the expected Mendelian frequency (12.5%), indicating that the absence of cardiac LpL did not cause embryonic lethality. In addition to genotyping mice by PCR, we performed a Southern blot on murine tail DNA to assess the presence of the second loxP site (Fig. 1B) . Hearts from hLpL0 mice had a dramatic reduction in LpL message compared with wild type, cre, and lox/lox mice, which expressed LpL in abundance (Fig. 1C) . In addition, hearts from hLpL0 mice had 78% less LpL activity than wild type (p Ͻ 0.001) (Fig. 1D) . The small amount of residual LpL might be because of translocation of LpL from other organs such as muscle or adipose tissue. However, it probably is more because of the expression of the LpL gene in non-myocytes, e.g. macrophages or adipocytes, found in the heart (18) . LpL expression and protein content in skeletal muscle and adipose tissue did not differ between the groups (Fig. 1, E and F) .
Male hLpL0 mice had significantly elevated plasma TG compared with wild type controls (n ϭ 9) (192 Ϯ 24 versus 76 Ϯ 5 mg/dl; p Ͻ 0.001) ( Table I ). This was attributed to an increase in VLDL-TG as indicated by fast performance liquid chromatography analysis ( Fig. 2A) . Female hLpL0 mice tended to have increased TG, but this was not significant (p ϭ 0.15) ( Table I) . We obtained postheparin plasma from hLpL0 and wild type mice (n ϭ 5) and assayed for LpL activity (Fig. 2C) and protein (Fig. 2D) . Although in hLpL0 mice LpL activity was 16% less and LpL protein was 20% less, this was not statistically significant. Postheparin plasma LpL activity was 58 Ϯ 7 versus 49 Ϯ 5 mmol/ml/h, and mass was 115 Ϯ 28 versus 92 Ϯ 17 ng/ml.
Lipoprotein TG and FA Metabolism-Plasma postprandial TG was increased markedly in the hLpL0 mice (Fig. 3A) . Plasma TG levels peaked 4 h following gavage and remained elevated in hLpL0 mice compared with wild type. Thus, the loss of LpL in the heart dramatically altered whole body metabolism of postprandial TG.
We assessed the tissue uptake of labeled VLDL and FFA. This was assessed over 5 min to allow us to determine the heart accumulation of [
14 C]palmitate and [ 3 H]TG-VLDL prior to any recycling of the labels (4). Heart uptake of [ 3 H]VLDL-TG was decreased significantly by 72% in hLpL0 mice compared with wild type (Fig. 3B) , whereas heart uptake of [ 14 C]palmitate did not differ between the groups (Fig. 3C) . Despite the normal level of LpL activity, there was also a slight reduction in muscle VLDL uptake. Perhaps the hypertriglyceridemia led to extensive product inhibition of LpL in this tissue. Heart content of both TG and FA, but not cholesterol, was reduced in hLpL0 hearts (Fig. 3, D and E) . Therefore, the loss of cardiac LpL dramatically decreased the uptake of lipoprotein-derived FA and reduced heart lipid content.
Northern Blot Analysis of Genes Involved in Lipid and
Glucose Metabolism-To determine whether the decrease in lipoprotein TG uptake by the heart altered cardiac gene expression, we assessed the expression of several genes involved in lipid and glucose metabolism. We observed a decrease in the expression of ACO, carnitine palmitoyltransferase 1, FATP, and CD36 in hearts from hLpL0 mice (Fig. 4, A-D) . The expression of PPAR␥, but not PPAR␣, was reduced markedly (Fig. 4, E and F) . Thus, the loss of LpL altered the expression of PPAR␣-responsive genes and decreased PPAR␥ expression.
GLUT4, but not GLUT1 expression, was increased in these hearts (Fig. 4, G and H) . Moreover, PDK4 expression was reduced markedly in hearts lacking LpL (Fig. 4I) . These data suggest that hearts lacking LpL have increased glucose oxidation. Surprisingly, IRS-1 expression was reduced dramatically and IRS-2 expression was increased (Fig. 4, J and K) . To determine whether the loss of IRS-1 expression affected downstream insulin signaling molecules required for the translocation of GLUT4 transporters, we assayed for phosphorylated Akt/PKB protein content by immunoblotting. Active Akt/PKB protein content did not differ between groups during the fasted (Fig. 5A) or fed (Fig. 5B) state.
In Vivo Glucose Metabolism in hLpL0 Hearts-To determine the effects of heart LpL deletion on glucose metabolism in vivo, we studied basal uptake of 2-deoxy-D-[1-
14 C]glucose into con- trol and hLpL0 hearts in fasting mice. The two groups of mice had identical basal plasma glucose (Table I ) and insulin levels (Fig. 6A) . However, there was a dramatic increase in basal glucose uptake into hLpL0 hearts, an 8-fold increase (Fig. 6B) . Greater cardiac glucose metabolism is consistent with elevated expression of GLUT4 and reduction in PDK4 in the hLpL0 mice. Thus, LpL deficiency changed heart substrate preference.
We next assessed whether glucose uptake also was altered under stimulated conditions, i.e. in the presence of high concentrations of insulin. In part, this allowed us to assess the effects of the alterations in IRS expression. A 2-h hyperinsulinemic-euglycemic clamp experiment was conducted in awake hLpL0 mice and wild type littermates. Insulin-stimulated whole body glucose turnover (Fig. 6C ) and insulin action in liver (data not shown) were not altered in the hLpL0 mice, indicating that heart-specific deletion of LpL did not affect whole body glucose homeostasis. In contrast, insulin-stimulated heart-specific glucose uptake, glycolysis, and glycogen synthesis showed a tendency to increase in the hLpL0 mice as compared with the wild type mice (p ϭ 0.08 for both glucose uptake and glycolysis) (Fig. 6, D-F) . Thus, the most dramatic changes in cardiac glucose metabolism were found under basal conditions. DISCUSSION We have created a cardiac specific LpL knock out mouse using cre-loxP gene targeting. hLpL0 mice are viable and have normal development. We observed several important physiological roles of LpL using this mouse model. 1) Cardiac LpL is an important modulator of plasma TG levels. 2) Decreased uptake of lipopro- tein-derived FA reduced expression of genes required for FA oxidation. 3) Cardiac glucose uptake was increased without alteration in whole body glucose homeostasis. 4) Surprisingly, the insulin-signaling pathway was altered and IRS-1 expression was reduced while IRS-2 expression was increased.
Our data show an important and little appreciated role of heart LpL in regulating plasma TG levels. hLpL0 mice exhibited increased plasma TG levels, even though postheparin plasma LpL activity and mass were similar to wild type. The observation that heart LpL is a major determinant of plasma lipoprotein levels is surprising because it is widely believed that most TG hydrolysis occurs in skeletal muscle and adipose capillaries (19) . However, our observations are consistent with studies by Levak-Frank et al. (6) who reported that moderate LpL expression in the heart alone was sufficient to maintain normal plasma TG levels despite the absence of skeletal muscle and adipose LpL and reduced postheparin plasma LpL activity. Thus, cardiac LpL has a tremendous capacity for lipoprotein TG hydrolysis and appears to be more active than LpL in other tissue capillary beds. The reasons for this are unclear but might relate to differences in cardiac capillary blood flow, the relative density of LpL molecules, or reduced FA inhibition of LpL because of efficient uptake of FA via CD36 and/or other FA transport proteins (20) .
The loss of LpL expression in the heart markedly decreased the clearance of postprandial TG (Fig. 3A) . In contrast, mice heterozygous for the LpL gene have relatively normal postprandial TG clearance despite having a much greater defect in total body LpL (8) . These data highlight the importance of cardiac LpL in regulating plasma TG levels as well as clearing postprandial lipoproteins.
The high energy demands of the heart require a readily accessible and large supply of FA for the production of ATP. FA bound to albumin are thought to be the primary source of FA delivered to the heart (3) with a second source of FA coming from lipoproteins. Because acute inhibition of LpL activity decreased heart-specific uptake of TG-derived FA (4), this second pathway must be highly dependent on LpL. The effects of chronic ablation of heart LpL on cardiac gene expression had not been investigated until now. By knocking out LpL specifically in cardiac muscle, we have shown that loss of lipoprotein TG uptake by the heart down-regulates the expression of key enzymes involved in FA metabolism including ACO, FATP1, FIG. 5 . Akt activation in hLpL0 hearts. A, immunoblot of phosphorylated Akt/PKB (Ser-473) protein content in heart homogenates from 6-h fasted male wild type and hLpL0 mice. B, immunoblot of phosphorylated Akt/PKB in heart homogenates from fed male mice. The intensity of the bands for phosphorylated Akt was compared with that for the control actin by densitometric scanning. The averages intensities between the wild type and hLpL0 two mice were within 10%. , n ϭ 5) . B, basal glucose uptake in hLpL0 (n ϭ 10) hearts was assessed after a single bolus injection of 2-deoxyglucose. C, insulin-stimulated whole body glucose turnover in the wild type and hLpL0 mice did not differ between groups. D, insulinstimulated glucose uptake and insulinstimulated glycolysis (p ϭ 0.08) (E). F, insulin-stimulated glycogen synthesis in the heart did differ between wild type and hLpL0 mice. Values are means Ϯ S.E. and CD36. This occurred with no change in PPAR␣ expression, consistent with LpL loss leading to decreased activation of this transcription factor. Thus, LpL provides lipid for intracellular gene regulation. Unexpectedly, PPAR␥ expression was markedly down-regulated in hLpL0 hearts. The reasons for this are unclear.
Several groups of long chain FA have been implicated as natural ligands for PPAR␣ and PPAR␥ (21) . These include saturated and unsaturated FA and eicosanoid metabolites of polyunsaturated fatty acids (21) . The reduced expression of PPAR␣-regulated genes with no change in PPAR␣ mRNA in hLpL0 hearts suggests that LpL-mediated hydrolysis of TGrich lipoproteins is providing a ligand for PPAR␣ activation. This finding suggests that lipoprotein-derived lipids, perhaps in preference to albumin-associated FA or other molecules, activate PPAR␣. These results are in agreement with some recent in vitro data implicating LpL-generated fatty acids as activators of PPARs in cultured endothelial cells and macrophages (22, 23) . However, our data demonstrate that LpL activation of PPARs occurs (a) in vivo, (b) in the presence of physiologic levels of plasma lipoproteins and FA, and (c) with amounts of LpL expressed in normal hearts.
Interestingly, hLpL0 hearts exhibited a trend toward increased GLUT4 expression (p ϭ 0.07). Hearts overexpressing LpL (24), the converse situation, had a decrease in GLUT4 gene expression. In addition, GLUT4 mRNA was decreased in hearts overexpressing PPAR␣ (25) . Acute regulation of GLUT4 actions is primarily via insulin-mediated translocation of this protein from intracellular vesicles to the plasma membrane (26, 27) . Increased intracellular lipids are thought to interfere with insulin signaling, perhaps via alteration in protein kinase C phosphorylation of IRS (28) . Our data suggest, that aside from the well known modulation of insulin signaling by muscle lipid content (28) , lipid regulation of glucose transport also occurs via changes in gene transcription.
The changes PDK4 expression suggested that glucose oxidation was increased in hLpL0 hearts. Indeed, despite normal plasma glucose and insulin, heart glucose uptake was dramatically elevated in fasting mice (Fig. 6, A and B) . Interestingly, hyperinsulinemic-euglycemic clamps showed a tendency toward greater cardiac glucose uptake and metabolism in hLpL0 hearts; however, the differences between wild type and hLpL0 animals were much less dramatic than those observed under basal conditions. PDK4 is a known PPAR␣-response gene that tightly regulates glucose oxidation in the heart. Decreased expression of this gene in the hLpL0 hearts indicated increased glucose oxidation. GLUT4 primarily mediates insulin-stimulated but not basal glucose uptake. Therefore, it is possible that other GLUTs are responsible for the increase glucose uptake in hLpL0 hearts. Taken together, our results suggest that reduced cardiac lipid metabolism because of the deletion of cardiac LpL led to transcriptional changes associated with greater cardiac glucose metabolism. Thus, increased glucose utilization substituted for reduced TG-derived FA metabolism in these hearts. Surprisingly, hLpL0 hearts had reduced IRS-1 and increased IRS-2 gene expression. Normally, IRS-1 is the primary mediator of insulin signaling in the heart (29) . IRS-2 is also expressed in the heart (29) but is more important in the pancreas and liver. Within an individual tissue, the actions of these signaling molecules are not thought to be compensatory (30, 31) . However, our data suggest that increased IRS-2 expression in the hLpL0 hearts allowed for normal insulin signaling despite the reduction in IRS-1 expression. Akt/PKB phosphorylation, which is required for intracellular trafficking of GLUT4 to the plasma membrane (32), was normal in hLpL0 hearts. Moreover, we observed normal cardiac glucose metabolism in the hyperinsulinemic-euglycemic clamp studies.
Greater uptake of glucose under basal conditions was also observed in IRS-1 knock-out mice. They have elevated basal uptake of 2-deoxyglucose into skeletal muscle (33) but reduced insulin-stimulated glucose uptake (34) . GLUT1 and GLUT4 protein were normal, but other GLUTs were not assessed. Thus, compensatory processes that occur with IRS-1 loss elevated basal glucose uptake both in IRS-1 knock-out and hLpL0 mice. Whereas this compensation could be mediated by the IRS-2 up-regulation, it is also possible that non-insulin-stimulated pathways are involved. Such pathways were found in mice having heart-specific deletion of insulin receptors (35) . Despite loss of insulin actions, basal glucose uptake in these hearts was normal. The functional consequences of decreased IRS-1 expression in the heart have not been reported.
A reduction in FA oxidation and increased glucose utilization by the heart has been observed in several pathological conditions including ischemia/reperfusion injury and cardiac hypertrophy (36) . In our model, loss of LpL in the heart increased glucose utilization. This finding suggests that changes in glucose metabolism are driven by an initial depression of FA uptake and demonstrate the interdependence of glucose and FA metabolism. Perhaps for this reason, we have found no alterations in cardiac functions in these mice because the hearts have switched substrate preference from FA to glucose.
In summary, we have created for the first time mice with a tissue-specific deletion of LpL of the heart. Studies in these mice show that cardiac LpL is important for regulating plasma TG levels as well as clearing postprandial lipoproteins. LpL generates lipolysis products that modulate PPAR actions. Finally, LpL activity regulates metabolic switching between glucose and FA uptake in the heart.
